Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use

Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use

Abstract Ibrutinib‐based combination therapy with high‐dose methotrexate (HD‐MTX) has recently shown clinical activity against relapse/refractory (R/R) primary central nervous system lymphoma (PCNSL). Herein, we report our real‐world experience of treating 11 newly diagnosed PCNSL patients with the...

Full description

Bibliographic Details
Main Authors: Feili Chen, Diwen Pang, Hanguo Guo, Qiuxiang Ou, Xue Wu, Xinmiao Jiang, Xiaojuan Wei, Sichu Liu, Ling Huang, Zhanli Liang, Dong Zhou, Wenyu Li
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Cancer Medicine
Online Access:https://doi.org/10.1002/cam4.3499

Internet

https://doi.org/10.1002/cam4.3499

Similar Items